Among several bis-intercalator anti-cancer compounds tested in vitro against the DMS 114 strain of human small lung cancer cells, researchers identified a high performance compound which required the least concentration in order to achieve a 50% or greater cancer cell kill rate. This strong activity against human small lung cancer cells is a significant achievement given that lung cancer kills more Americans annually than any other type of cancer, according to the National Cancer Institute... PhytoMedical's Press Release-Jan 22, 2008
PhytoMedical, Patented Anti-Cancer Compounds Kill Lung Cancer Cells
January 22, 2008 - PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6) announced that its patented bis-intercalator anti-cancer compound achieved a 50% or greater cancer cell kill rate in new in vitro studies of the DMS 114 strain of human small lung cancer cells, an important outcome given lung cancer’s high mortality rate and the lack of effective treatment options(...)Among several bis-intercalator anti-cancer compounds tested in vitro against the DMS 114 strain of human small lung cancer cells, researchers identified a high performance compound which required the least concentration in order to achieve a 50% or greater cancer cell kill rate. This strong activity against human small lung cancer cells is a significant achievement given that lung cancer kills more Americans annually than any other type of cancer, according to the National Cancer Institute... PhytoMedical's Press Release-
Among several bis-intercalator anti-cancer compounds tested in vitro against the DMS 114 strain of human small lung cancer cells, researchers identified a high performance compound which required the least concentration in order to achieve a 50% or greater cancer cell kill rate. This strong activity against human small lung cancer cells is a significant achievement given that lung cancer kills more Americans annually than any other type of cancer, according to the National Cancer Institute... PhytoMedical's Press Release-
